SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Abamectin Liquid Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Abamectin Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Veterinary product

1.3 Details of the supplier of the safety data sheet
   Company : MSD
               Kilsheelan
               Clonmel Tipperary, IE
   Telephone : 353-51-601000
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Acute toxicity, Category 4 : H332: Harmful if inhaled.
   Specific target organ toxicity - repeated exposure, Category 2 : H373: May cause damage to organs through prolonged or repeated exposure.
   Short-term (acute) aquatic hazard, Category 1 : H400: Very toxic to aquatic life.
   Long-term (chronic) aquatic hazard, Category 1 : H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms : 
   Signal word : Warning
   Hazard statements : H332 Harmful if inhaled.
                      H373 May cause damage to organs through prolonged or repeated exposure.
                      H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements:

**Prevention:**
P271 Use only outdoors or in a well-ventilated area.
P273 Avoid release to the environment.

**Response:**
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/doctor if you feel unwell.
P314 Get medical advice/attention if you feel unwell.
P391 Collect spillage.

Hazardous components which must be listed on the label:
Abamectin (combination of avermectin B1a and avermectin B1b)

2.3 Other hazards
None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abamectin (combination of avermectin B1a and avermectin B1b)</td>
<td>71751-41-2</td>
<td>606-143-00-0</td>
<td></td>
<td>Acute Tox. 2; H300</td>
<td>&gt;= 1 - &lt; 2.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acute Tox. 1; H330</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acute Tox. 3; H311</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Repr. 2; H361fd</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>STOT RE 1; H372</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(Central nervous system)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Aquatic Acute 1; H400</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Aquatic Chronic 1; H410</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>M-Factor (Acute aquatic toxicity): 10,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>M-Factor (Chronic aquatic toxicity): 10,000</td>
<td></td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

**Protection of first-aiders:** First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

**If inhaled:** If inhaled, remove to fresh air.  
If not breathing, give artificial respiration.  
If breathing is difficult, give oxygen.  
Get medical attention.

**In case of skin contact:** In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.

**In case of eye contact:** Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

**If swallowed:** If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

**Risks:** Harmful if inhaled.  
May cause damage to organs through prolonged or repeated exposure.

### 4.3 Indication of any immediate medical attention and special treatment needed

**Treatment:** Treat symptomatically and supportively.

---

**SECTION 5: Firefighting measures**

### 5.1 Extinguishing media

**Suitable extinguishing media:** Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO2)  
Dry chemical

**Unsuitable extinguishing media:** None known.

### 5.2 Special hazards arising from the substance or mixture

**Specific hazards during firefighting:** Exposure to combustion products may be a hazard to health.

**Hazardous combustion prod-** Carbon oxides
5.3 Advice for firefighters

Special protective equipment for firefighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g. by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
- See Engineering measures under EXPOSURE
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Abamectin Liquid Formulation

Version 4.4  Revision Date: 10.10.2020  SDS Number: 1228550-00012  Date of last issue: 23.03.2020

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling:
- Do not breathe mist or vapours.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
- Keep container tightly closed.
- Do not eat, drink or smoke when using this product.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers:
- Keep in properly labelled containers. Keep tightly closed.
- Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.

Advice on common storage:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Organic peroxides
  - Explosives
  - Gases

7.3 Specific end use(s)

Specific use(s):
- No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abamectin (combination of avermectin B1a and avermectin B1b)</td>
</tr>
<tr>
<td>CAS-No.</td>
</tr>
<tr>
<td>71751-41-2</td>
</tr>
<tr>
<td>Value type (Form of exposure)</td>
</tr>
<tr>
<td>TWA</td>
</tr>
<tr>
<td>Control parameters</td>
</tr>
<tr>
<td>30 µg/m³ (OEB 3)</td>
</tr>
<tr>
<td>Basis</td>
</tr>
<tr>
<td>Internal</td>
</tr>
</tbody>
</table>

Wipe limit: 300 µg/100 cm² - Internal
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Abamectin Liquid Formulation

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerides, mixed decanoyl and octanoyl</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>177.79 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>25.21 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>43.84 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>12.61 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>12.61 mg/kg bw/day</td>
</tr>
</tbody>
</table>

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerides, mixed decanoyl and octanoyl</td>
<td>Oral (Secondary Poisoning)</td>
<td>0.03 mg/kg food</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Equipment should conform to I.S. EN 14387
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Abamectin Liquid Formulation

Version 4.4 Revision Date: 10.10.2020 SDS Number: 1228550-00012 Date of last issue: 23.03.2020
Date of first issue: 18.01.2017

Filter type : Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties
Appearance : liquid
Colour : light yellow
Odour : characteristic
Odour Threshold : No data available
pH : No data available
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
Flash point : No data available
Evaporation rate : No data available
Flammability (solid, gas) : Not applicable
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapour pressure : No data available
Relative vapour density : No data available
Relative density : No data available
Density : 0.90 - 0.94 g/cm3
Solubility(ies) : 
Water solubility : insoluble
Partition coefficient: n-octanol/water : Not applicable
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity : 
Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information
Flammability (liquids) : No data available
Abamectin Liquid Formulation

Molecular weight : No data available
Particle size : Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : None known.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Information on likely routes of exposure :
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Harmful if inhaled.

Product:
Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 2.3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method
Components:

Abamectin (combination of avermectin B1a and avermectin B1b):

Acute oral toxicity: LD50 (Rat): 24 mg/kg
LD50 (Mouse): 10 mg/kg
LDLo (Monkey): 24 mg/kg
Symptoms: Dilatation of the pupil

Acute inhalation toxicity: LC50 (Rat): 0.023 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rat): 330 mg/kg
LD50 (Rabbit): 2,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:

Abamectin (combination of avermectin B1a and avermectin B1b):

Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Abamectin (combination of avermectin B1a and avermectin B1b):

Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Abamectin (combination of avermectin B1a and avermectin B1b):

Test Type: Maximisation Test
Exposure routes: Skin contact
Result: Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.
Components:

Abamectin (combination of avermectin B1a and avermectin B1b):

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Test system: Chinese hamster lung cells
  Result: negative
- Test Type: Alkaline elution assay
  Result: negative

Genotoxicity in vivo:
- Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
  Species: Mouse
  Application Route: Intraperitoneal injection
  Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Abamectin (combination of avermectin B1a and avermectin B1b):

Species: Rat
Application Route: Oral
Exposure time: 105 weeks
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 93 weeks
Result: negative

Reproductive toxicity
Not classified based on available information.

Components:

Abamectin (combination of avermectin B1a and avermectin B1b):

Effects on fertility:
- Test Type: Fertility
  Species: Rat, male
  Application Route: Oral
  Result: Effects on fertility
- Test Type: Two-generation reproduction toxicity study
  Species: Rat
  Application Route: Oral
  Early Embryonic Development: NOAEL: 0.12 mg/kg body weight
  Result: Fetotoxicity
Abamectin Liquid Formulation

Effects on foetal development:
Test Type: Embryo-foetal development
Species: Mouse
Application Route: Oral
General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Cleft palate
Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 2 mg/kg body weight
Result: Cleft palate, Teratogenic effects, Reduced embryonic survival
Remarks: Adverse developmental effects were observed

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
Result: Teratogenic effects

Reproductive toxicity - Assessment:
Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Exposure routes: Ingestion
Target Organs: Central nervous system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Species: Rat
NOAEL: 1.5 mg/kg
Application Route: Oral
Exposure time: 24 Months
Target Organs: Central nervous system
Symptoms: Tremors, ataxia
Species: Mouse
NOAEL : 4.0 mg/kg
Application Route : Oral
Exposure time : 24 Months
Target Organs : Central nervous system
Symptoms : Tremors, ataxia

Species : Dog
NOAEL : 0.25 mg/kg
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Target Organs : Central nervous system
Symptoms : Tremors, weight loss
Remarks : mortality observed

Species : Monkey
NOAEL : 1.0 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Central nervous system

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Abamectin (combination of avermectin B1a and avermectin B1b):
Ingestion : Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing

SECTION 12: Ecological information

12.1 Toxicity

Components:

Abamectin (combination of avermectin B1a and avermectin B1b):
Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l
Exposure time: 96 h

LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l
Exposure time: 96 h

LC50 (Cyprinus carpio (Carp)): 42 µg/l
Exposure time: 96 h

LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l
Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates: EC50 (Americamysis): 0.022 µg/l
Exposure time: 96 h
EC50 (Daphnia magna (Water flea)): 0.34 µg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h

M-Factor (Acute aquatic toxicity): 10,000

Toxicity to microorganisms: EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

Toxicity to fish (Chronic toxicity): NOEC: 0.52 µg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC: 0.03 µg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
NOEC: 0.0035 µg/l
Exposure time: 28 d
Species: Mysidopsis bahia (opossum shrimp)

M-Factor (Chronic aquatic toxicity): 10,000

12.2 Persistence and degradability

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Stability in water: Hydrolysis: 50 %(< 12 h)

12.3 Bioaccumulative potential

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Bioaccumulation: Bioconcentration factor (BCF): 52
Partition coefficient: n-octanol/water: log Pow: 4

12.4 Mobility in soil

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Distribution among environ- log Koc: > 3.6
mental compartments

12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
ADN : UN 3082
ADR : UN 3082
RID : UN 3082
IMDG : UN 3082
IATA : UN 3082

14.2 UN proper shipping name
ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b))
ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b))
RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b))
IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b))
IATA : Environmentally hazardous substance, liquid, n.o.s. (Abamectin (combination of avermectin B1a and avermectin B1b))
14.3 Transport hazard class(es)

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

ADN
Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

ADR
Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

RID
Tunnel restriction code : (-)

IMDG
Packing group : III
Labels : 9

IATA (Cargo)
Packing instruction (cargo aircraft) : 964
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

IATA (Passenger)
Packing instruction (passenger aircraft) : 964
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards

ADN
Environmentally hazardous : yes

ADR
Environmentally hazardous : yes
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Abamectin Liquid Formulation

Version 4.4
Revision Date: 10.10.2020
SDS Number: 1228550-00012
Date of last issue: 23.03.2020
Date of first issue: 18.01.2017

RID
Environmentally hazardous: yes

IMDG
Marine pollutant: yes

IATA (Passenger)
Environmentally hazardous: yes

IATA (Cargo)
Environmentally hazardous: yes

14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII)
: Conditions of restriction for the following entries should be considered: Number on list 3
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).
REACH - List of substances subject to authorisation (Annex XIV)
: Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer
: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast)
: Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals
: Not applicable

<table>
<thead>
<tr>
<th>E1</th>
<th>ENVIRONMENTAL HAZARDS</th>
<th>Quantity 1</th>
<th>Quantity 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>100 t</td>
<td>200 t</td>
</tr>
</tbody>
</table>

Other regulations:
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS: not determined

DSL: not determined

IECSC: not determined
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Abamectin Liquid Formulation

Version: 4.4
Revision Date: 10.10.2020
SDS Number: 1228550-00012
Date of last issue: 23.03.2020
Date of first issue: 18.01.2017

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information:
Items where changes have been made to the previous version
are highlighted in the body of this document by two vertical
lines.

Full text of H-statements

H300: Fatal if swallowed.
H311: Toxic in contact with skin.
H330: Fatal if inhaled.
H361fd: Suspected of damaging fertility. Suspected of damaging the
unborn child.
H372: Causes damage to organs through prolonged or repeated
exposure if swallowed.
H400: Very toxic to aquatic life.
H410: Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox.: Acute toxicity
Aquatic Acute: Short-term (acute) aquatic hazard
Aquatic Chronic: Long-term (chronic) aquatic hazard
Repr.: Reproductive toxicity
STOT RE: Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labeling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a
test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative Structure-Activity Relationship);
Abamectin Liquid Formulation

Version 4.4  Revision Date: 10.10.2020  SDS Number: 1228550-00012  Date of last issue: 23.03.2020  Date of first issue: 18.01.2017

Sources of key data used to compile the Safety Data Sheet:

Classification of the mixture:
- Acute Tox. 4: H332  Calculation method
- STOT RE 2: H373  Calculation method
- Aquatic Acute 1: H400  Calculation method
- Aquatic Chronic 1: H410  Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN